181 related articles for article (PubMed ID: 38216952)
1. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
[TBL] [Abstract][Full Text] [Related]
4. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
[TBL] [Abstract][Full Text] [Related]
5. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
[TBL] [Abstract][Full Text] [Related]
6. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
[TBL] [Abstract][Full Text] [Related]
7. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
8. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
[TBL] [Abstract][Full Text] [Related]
9. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
[TBL] [Abstract][Full Text] [Related]
10. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
11. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
Ulase D; Behrens HM; Röcken C
Virchows Arch; 2024 May; ():. PubMed ID: 38748262
[TBL] [Abstract][Full Text] [Related]
12. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
[TBL] [Abstract][Full Text] [Related]
13. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
14. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract][Full Text] [Related]
15. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
[TBL] [Abstract][Full Text] [Related]
16. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
17. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
Jeong BC; Chalfin HJ; Lee SB; Feng Z; Epstein JI; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
Eur Urol; 2015 Feb; 67(2):342-6. PubMed ID: 24968968
[TBL] [Abstract][Full Text] [Related]
19. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
